<DOC>
	<DOCNO>NCT02725502</DOCNO>
	<brief_summary>Type 1 diabetes autoimmune disorder characterize beta cell destruction result insulinopenia . Currently treat insulin . Dipeptidylpeptidase inhibitor ( DPP4 inhibitor e.g . linagliptin &amp; sitagliptin ) use type 2 diabetes mellitus ( T2DM ) traditionally . Previous study show also effective type 1 diabetes mellitus ( T1DM ) , mechanism action well understood . This study evaluate possible mechanism action linagliptin T1DM patient .</brief_summary>
	<brief_title>Incretin Axis Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Glucose important physiologic substance involve regulation insulin release . The effect glucose beta cell dose relate . Dose-dependent increase concentration insulin C-peptide rate insulin secretion observe oral intravenous glucose load 1.4 unit insulin , average , secrete response oral glucose load small 12 g. The insulin secretory response great oral compare intravenous glucose administration . This difference insulin secretion know incretin effect . This enhanced response oral glucose interpret indication absorption glucose way gastrointestinal tract stimulate release hormone mechanism ultimately enhance sensitivity beta cell glucose . The release insulin beta cell meal facilitate number gastrointestinal peptide hormone , include GIP ( Glucose dependent insulinotropic peptide ) , cholecystokinin , GLP1 ( Glucagon like peptide 1 ) . These hormone release small-intestinal endocrine cell postprandialy travel bloodstream reach beta cell , act second messenger increase sensitivity islet cell glucose . In general , hormone secretagogues , effect evident presence hyperglycemia . This incretin effect could account great beta-cell response observe oral oppose intravenous glucose administration . GLP1 , potent incretin peptide , lower glucose patient T2DM stimulate endogenous insulin secretion perhaps inhibit glucagon secretion gastric emptying . Treatment supra physiologic dos GIP hyperglycemia show augment insulin secretion normal human individual diabetes mellitus . Although cholecystokinin ability augment insulin secretion human , firmly establish whether incretin physiologic level . Its effect also see largely pharmacological dos . Type 1 diabetes ( T1DM ) characterize autoimmune pancreatic Î² cell destruction insulin deficiency result hyperglycemia . Insulin mainstay treatment T1DM . There study show effectiveness OHA ( oral hypoglycemic agent ) T1DM . Linagliptin dipeptidyl peptidase 4 ( DPP4 ) inhibitor . It increase endogenous glucagon like peptide 1 level inhibit rapid metabolism dipeptidyl peptidase 4 enzyme . It currently Food Drug Administration ( FDA ) approve treatment Type 2 diabetes ( T2DM ) mono therapy combination insulin oral hypoglycemic agent . Increasing endogenous glucagon like peptide 1 level patient T2DM show significantly improve postprandial glucose level increase glucose-dependent insulin release reduce glucagon level . Studies show sitagliptin , DPP4 inhibitor effective T1DM . But mechanism action unknown . In study investigator want investigate effect linagliptin , another DPP4 inhibitor glycaemic profile , HbA1C glycaemic variability patient T1DM . The investigator also assess GLP1 glucagon response mixed meal test identify potential mechanism novel form therapy . These come parameter compare placebo treat T1DM patient . During study patient monitor adverse effect like nausea , vomit , pancreatitis . Serum urea , creatinin , amylase lipase monitor monthly .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Male female adult , age 15 30 year Duration type 1 Diabetes Mellitus 6 month , establish medical history Current treatment multiple injection insulin least 3 month prior screen visit ; use insulin last 1 month HbA1c &lt; 8 % Body mass index ( BMI ) &lt; 25 kg/mt2 Euthyroid patient . If thyroid dysfunction present thyroid function test ( TFT ) normal time study ( medication ) On pramlintide , metformin , GLP1 agonist DPP4 inhibitor . If take drug stop 2 wk prior study . On prokinetics &amp; proton pump inhibitor ( PPI ) . If take drug stop 2 wk prior study Creatinine &gt; 1.5 mg/dl calculate creatinin clearance &lt; 50 ml/min overt proteinuria . Fasting blood glucose ( FBG ) &lt; 72 &gt; 180 day mixed meal test ( MMT ) Pregnant Seriously ill patient Presence gastroparesis ( history suggestive autonomic neuropathy gastroparesis gastric empty study do rule ) Type 1 Diabetes Mellitus le 6 month duration Presence celiac disease</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>T1DM</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>mix meal test</keyword>
</DOC>